3 years of tralokinumab treatment provides long term disease control as demonstrated by clinically meaningful outcomes in modera te to severe atopic dermatitis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s142, 2023. DOI: 10.25251/skin.7.supp.142. Disponível em: https://skin.dermsquared.com/skin/article/view/2028. Acesso em: 4 apr. 2025.